Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma ...Middle East

ROCKVILLE, Md. and SUZHOU, China, Dec. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic,...

Hence then, the article about innovent announces the phase 3 orient 16 study results published in jama evaluating sintilimab in combination with chemotherapy for the first line treatment of gastric or gastroesophageal junction g gej adenocarcinoma was published today ( Wednesday 06/12/2023 - 03:20 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma )

Also on site :

• Who Is Anthony Kazmierczak? Ilhan Omar Attack Suspect Identified
• Bobby Bones Is Barely Recognizable After Rescuing a Stranger During Winter Storm Fern
• 2000s Heavy Metal Band Aims for ‘Suspended Illusion’ on Its 20th Anniversary Tour